Abstract
Myelodysplastic syndromes (MDS) are characterized by an ineffective hematopoiesis and functional abnormalities of hematopoietic lineages. Patients with MDS present with cytopenia(s) associated with morphological dysplasia and /or increase in number of blasts, and can progress to acute myeloid leukemia. The pathogenesis of MDS is exceedingly complex and involves the hematopoietic stem cells, bone marrow microenvironment and an interaction between these two compartments. The laboratory diagnostic strategy in MDS has evolved significantly over the years from a purely morphological one based almost exclusively on peripheral blood smear and bone marrow aspirate cytology to the integrated multiparametric approach used in the 2001 and 2008 WHO classification schemes. An evolution has also occurred in the prognostic assessment and the evaluation of treatment response to include novel disease related factors as well as patient specific characteristics such as non-hematologic comorbidities. This progress in clinically relevant subclassification of MDS and inclusion of specific variables related to treatment response are particularly important considering the increasing treatment options available for MDS.
This review is largely focused on the diagnostic approach to MDS including discussion of the significance of cytogenetic/genetic and immunophenotypic features. We present the overview of the minimal diagnostic criteria for diagnosing MDS and a detailed description the current World Health Organization (WHO) classification scheme.
Keywords: Myelodysplastic syndromes (MDS), refractory cytopenia with unilineage dysplasia, refractory cytopenia with multilineage dysplasia, refractory anemia with excess blasts, 5q- syndrome, MDS, Unclassifiable, pediatric MDS, histopathology, immunohistochemistry, flow cytometry, cytogenetics
Current Pharmaceutical Design
Title:World Health Organization Classification of Myelodysplastic Syndromes
Volume: 18 Issue: 22
Author(s): Magdalena Czader and Attilio Orazi
Affiliation:
Keywords: Myelodysplastic syndromes (MDS), refractory cytopenia with unilineage dysplasia, refractory cytopenia with multilineage dysplasia, refractory anemia with excess blasts, 5q- syndrome, MDS, Unclassifiable, pediatric MDS, histopathology, immunohistochemistry, flow cytometry, cytogenetics
Abstract: Myelodysplastic syndromes (MDS) are characterized by an ineffective hematopoiesis and functional abnormalities of hematopoietic lineages. Patients with MDS present with cytopenia(s) associated with morphological dysplasia and /or increase in number of blasts, and can progress to acute myeloid leukemia. The pathogenesis of MDS is exceedingly complex and involves the hematopoietic stem cells, bone marrow microenvironment and an interaction between these two compartments. The laboratory diagnostic strategy in MDS has evolved significantly over the years from a purely morphological one based almost exclusively on peripheral blood smear and bone marrow aspirate cytology to the integrated multiparametric approach used in the 2001 and 2008 WHO classification schemes. An evolution has also occurred in the prognostic assessment and the evaluation of treatment response to include novel disease related factors as well as patient specific characteristics such as non-hematologic comorbidities. This progress in clinically relevant subclassification of MDS and inclusion of specific variables related to treatment response are particularly important considering the increasing treatment options available for MDS.
This review is largely focused on the diagnostic approach to MDS including discussion of the significance of cytogenetic/genetic and immunophenotypic features. We present the overview of the minimal diagnostic criteria for diagnosing MDS and a detailed description the current World Health Organization (WHO) classification scheme.
Export Options
About this article
Cite this article as:
Czader Magdalena and Orazi Attilio, World Health Organization Classification of Myelodysplastic Syndromes, Current Pharmaceutical Design 2012; 18 (22) . https://dx.doi.org/10.2174/1381612811209023149
DOI https://dx.doi.org/10.2174/1381612811209023149 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNAs in Tumorigenesis
Current Pharmaceutical Biotechnology Microglia Phenotype Diversity
CNS & Neurological Disorders - Drug Targets Expression of P-gp, MRP, LRP, GST-π and TopoIIα and Acquired Resistance to Cisplatin in Human Lung Adenocarcinoma Cells
Letters in Drug Design & Discovery New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors
Current Pharmaceutical Design Gedunin, A Neem Limonoid in Combination with Epalrestat Inhibits Cancer Hallmarks by Attenuating Aldose Reductase-Driven Oncogenic Signaling in SCC131 Oral Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Gene Therapeutic Approaches for Immune Modulation in AIDS
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry OPLS-DA as a Suitable Method for Selecting a Set of Gene Transcripts Discriminating RAS- and PTPN11-Mutated Cells in Acute Lymphoblastic Leukaemia
Combinatorial Chemistry & High Throughput Screening Editorial (Thematic Issue: Chronic Myeloid Leukemia: Reaching For the Cure)
Current Cancer Drug Targets Design of New Drug Molecules to be Used in Reversing Multidrug Resistance in Cancer Cells
Current Cancer Drug Targets Bioactive Compounds Containing Benzoxadiazole, Benzothiadiazole, Benzotriazole
Current Bioactive Compounds Production of Retroviral Vectors: Review
Current Gene Therapy Anti-proliferative Properties of miR-20b and miR-363 from the miR-106a-363 Cluster on Human Carcinoma Cells
MicroRNA RNA Interference: A New Targeted Tumour Therapy?
Current Cancer Therapy Reviews Substrates and Inhibitors of Human Multidrug Resistance Associated Proteins and the Implications in Drug Development
Current Medicinal Chemistry In Silico Discovery and Virtual Screening of Multi-Target Inhibitors for Proteins in Mycobacterium tuberculosis
Combinatorial Chemistry & High Throughput Screening A Review on the Synthetic Approach of Marinopyrroles: A Natural Antitumor Agent from the Ocean
Letters in Organic Chemistry Synthesis, Characterization and Evaluation of Cytotoxicity of New Aminophosphonic Acid Diesters in Human Leukemia Cells
Letters in Drug Design & Discovery Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay
Current Drug Targets Recent Progress on Chemical Biology of Pluripotent Stem Cell Selfrenewal, Reprogramming and Cardiomyogenesis
Recent Patents on Regenerative Medicine The Delivery of Biologically Active (Therapeutic) Peptides and Proteins into Cells
Current Medicinal Chemistry